Nangibotide
Also known as: LR12, Nangibotide, TLR4 antagonist peptide 1, TLT-1 peptide, Toll‑like receptor 4 inhibitory peptide
Source Nangibotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Nangibotide is a synthetic 12‑amino‑acid peptide that acts as an antagonist of Toll‑like receptor 4 (TLR4). It is being investigated for the treatment of sepsis, septic shock and hyper‑inflammatory states such as severe COVID‑19.
Mechanism of Action
Blocks the interaction of lipopolysaccharide with the TLR4-MD2 complex, inhibiting downstream NF-κB signaling and reducing pro‑inflammatory cytokine release
Routes of Administration
Goals & Uses
- SepsisInfectious DiseaseModerate
- Reduction of mortality in septic shockCritical Care / Anti InflammatoryModerate
- Septic ShockCritical CareModerate
- Attenuation of TREM-1-mediated hyperinflammationImmunomodulationModerate
- Organ dysfunction prevention in sepsisOrgan ProtectionModerate
- Biomarker-guided patient stratification in sepsisPrecision MedicineModerate
- Severe COVID‑19Viral InfectionLow
Contraindications
- Known hypersensitivity to nangibotide or excipientsAllergyHigh
- Known hypersensitivity to Nangibotide or any excipientsAllergyHigh
- Severe immunocompromised statesImmunologicalModerate
Adverse Effects
- Elevated liver enzymes (transient)HepaticRare
- HypotensionCardiovascularUncommonLow blood pressure
- Infusion site erythemaLocalCommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Infusion-related reactionsHypersensitivityUncommon
Drug Interactions
- Vasopressors (norepinephrine, vasopressin)Low
- CorticosteroidsModerate
- Concurrent high‑dose corticosteroidsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Pediatrics (<12 years)AgeRelative
- Pregnant or lactating womenReproductiveRelative
- Patients with chronic autoimmune conditions on immunosuppressantsComorbidityRelative
Regulatory Status
- European UnionInvestigationalPhase 2 clinical program ongoing
- United StatesInvestigationalUnder IND for sepsis; not FDA‑approved
- United KingdomInvestigationalClinical trials authorized by MHRA
Not approved by any regulatory agency. Investigated under clinical trial frameworks in Europe and the US. Phase 2 trial (ASTONISH) conducted in septic shock patients. Orphan or fast-track designations not publicly confirmed as of last available data.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Nangibotide?
Nangibotide is a synthetic 12‑amino‑acid peptide that acts as an antagonist of Toll‑like receptor 4 (TLR4). It is being investigated for the treatment of sepsis, septic shock and hyper‑inflammatory states such as severe COVID‑19.
What is Nangibotide used for?
Nangibotide is educationally associated with: Sepsis, Reduction of mortality in septic shock, Septic Shock, Attenuation of TREM-1-mediated hyperinflammation, Organ dysfunction prevention in sepsis, Biomarker-guided patient stratification in sepsis, Severe COVID‑19. Educational only — not medical advice.
How is Nangibotide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Nangibotide?
Reported adverse effects include: Elevated liver enzymes (transient), Hypotension, Infusion site erythema, Nausea, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Nangibotide?
Recorded contraindications: Known hypersensitivity to nangibotide or excipients, Known hypersensitivity to Nangibotide or any excipients, Severe immunocompromised states. Consult a qualified clinician before use.